Vancouver, British Columbia, Canada - TheNewswire - October 26, 2021 - Global Cannabis Applications Corp. ("GCAC" or the "Company") (CNSX:APP.CN) (FSE:2FA) (OTC:FUAPF), a leading medical cannabis chain-of-custody compliance and data platform, announced the live release of its web-based Prescriptii Patient Experience (PPE). The free-to-use website  empowers each cannabis consumer with data to help make better choices for their personal medical needs.
As part of its application process for a Health Canada Medical Cannabis Sales License , PPE is a Reddit-style web portal for medical cannabis consumers powered by an AI engine built by Curve Tech , creators of machine learning environments and prediction engines used by global e-commerce leaders like Shopify. The advanced algorithm analyzes over 600,000 verified data points from studies about cannabis, questionnaires, user reviews, and rankings of widely available strains for more than 80 medical conditions. Machine learning establishes links between the conditions and strains to create a data-driven picture of medical cannabis.
The proprietary heredity tree maps the origin and ancestry of over 9,000 strains and their chemical compound levels, including THC and CBD levels, Indica and Sativa ratios, and additional active compounds, such as CBN, CBC, CBG, and THCV. Two search modes make queries easy.
Prescriptii helps find strains rated best for certain conditions using PAIN to STRAIN. It analyzes a strain to see which conditions it works best for with STRAIN to PAIN and finds similar strains in the STRAIN to STRAIN area.
Prescriptii offers basic search results, and consumers can create an account for more comprehensive results, recommendations, and preferred strains.
GCAC CEO, Brad Moore says, “With the introduction of this free consumer service, we strive to improve customer knowledge and create confidence in this incredible plant. Additionally, for cultivators using Efixii, Prescriptii’s powerful AI engine can evaluate new strains as the AI engine ‘learns’ the effect of existing strains and can predict the behaviour of new strains.”
Initially available in English, Prescriptii will be accessible by consumers in Canada and the United States of America. Other languages and regional launch plans are forthcoming.
About Global Cannabis Applications Corp. “GCAC”
GCAC is a global leader in designing, developing, SaaS licensing and acquiring innovative data technologies for the medical cannabis industry. The Citizen Green and Efixii platforms are the world's first end-to-end - from patient to regulator - medical cannabis data solutions. They use six core technologies: mobile applications, artificial intelligence, RegTech, smart databases, Ethereum blockchain and GCAC smart rewards. These technologies transparently disclose cannabis chain-of-custody events, thereby enabling patients to provide crowd-sourced medical cannabis efficacy data. Driven by digital and cannabis industry experts, GCAC is focused on generating revenue from SaaS licensing its technology and acquiring high quality cannabis datasets that improve patient outcomes and to become the world’s largest cannabis efficacy data provider.
Phone: +1 (800) 409-5679
This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of GCAC. Forward-looking information is based on certain key expectations and assumptions made by the management of GCAC. Although management of the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because GCAC can give no assurance that they will prove to be correct. Forward-looking statements contained in this news release are made as of the date of this news release. GCAC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy and accuracy of this information.